Mandate

Vinge has advised Consolid on the establishment of Consolid Equity III

July 02, 2025 Private Funds

The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.

Consolid invests in high-potential business services companies, providing the expertise, ideas, and capital they need to grow and scale. By partnering closely with entrepreneurs, Consolid creates opportunities to innovate, tackle challenges, and build businesses that redefine their industries.

 

Vinge's team primarily consisted of Mattias Schömer, Marcus Andersson, Ulf Nilsson, Emelie Svanberg, Anton Sjökvist, Semir Omerbasic, Rebecka Margolin, Tobias Onegård Karlsson, Marcus Svärd, Saga Meyer Viklund, Emelie Zingmark and Lovisa Lagerkvist.

 

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025